JANX FY2024 EPS Forecast Raised by Cantor Fitzgerald

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Tuesday, December 3rd. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($1.28) per share for the year, up from their previous estimate of ($1.32). Cantor Fitzgerald has a “Overweight” rating and a $100.00 price objective on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year.

Several other equities research analysts have also weighed in on the stock. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. BTIG Research increased their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. Leerink Partners raised their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Stifel Nicolaus upped their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has an average rating of “Buy” and a consensus target price of $79.90.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $66.30 on Thursday. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.71. The business has a 50-day moving average of $50.21 and a 200-day moving average of $45.96. The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -56.67 and a beta of 3.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $29,000. Amalgamated Bank grew its position in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insiders Place Their Bets

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the completion of the sale, the insider now directly owns 7,000 shares in the company, valued at $296,310. This trade represents a 23.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 352,245 shares of company stock valued at $17,032,336 over the last 90 days. 29.40% of the stock is currently owned by insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.